Bibliography
- Kearon C. Natural history of venous thromboembolism. Circulation 2003;107:I22-30
- Geerts WH, Bergqvist D, Pineo GF, Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:381S-453S
- Prandoni P, Lensing AWA, Cogo A, The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7
- Kahn SR, Shrier I, Julian JA, Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 2008;149:698-707
- Ansell J, Hirsh J, Hylek E, Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:160S-98S
- Kearon C, Kahn SR, Agnelli G, Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:454S-545S
- Gomez-Outes A, Lecumberri R, Pozo C, Rocha E. New anticoagulants: focus on venous thromboembolism. Curr Vasc Pharmacol 2009;7:309-29
- Gross PL, Weitz JI. New antithrombotic drugs. Clin Pharmacol Ther 2009;86:139-46
- Bauer KA. New pentasaccharides for prophylaxis of deep vein thrombosis - pharmacology. Chest 2003;124:364S-70S
- Buller HR DJ, Gallus AS, Idrabiotaparinux, a biotinylated long-acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin. Blood 2008;112:18
- Buller HR, Cohen AT, Davidson B, Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007;357:1094-104
- Buller HR, Cohen AT, Davidson B, Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 2007;357:1105-12
- Available from: http://www.clinicaltrials.gov NCT0034561
- Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 2008;28:380-6
- Kubitza D, Becka M, Voith B, Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005;78:412-21
- Haas S. New anticoagulants – towards the development of an “ideal” anticoagulant. Vasa 2009;38:13-29
- Haas S. Rivaroxaban – an oral, direct factor Xa inhibitor: lessons from a broad clinical study programme. Eur J Haematol 2009;82:339-49
- Kakkar AK, Brenner B, Dahl OE, Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:31-9
- Lassen MR, Ageno W, Borris LC, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-86
- Turpie AG, Lassen MR, Davidson BL, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009;373:1673-80
- Eriksson BI, Kakkar AK, Turpie AG, Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br 2009;91:636-44
- Eriksson BI, Borris LC, Friedman RJ, Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-75
- Imberti D, Dallasta C. Clinical benefits of rivaroxaban for thromboprophylaxis after major orthopedic surgery. Adv Orthop 2008;1:8-16
- Available from: http://www.clinicaltrials.gov NCT00571649
- Lassen MR, Raskob GE, Gallus A, Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009;361:594-604
- Lassen MR, Gallus AS, Pineo GF, Raskob GE. The ADVANCE-2 Study: a randomized double-blind trial comparing apixaban with enoxaparin for thromboprophylaxis after total knee replacement. J Thromb Haemost 2009;7(Suppl 2): Abstract
- Available from: http://www.clinicaltrials.gov NCT00457002
- Available from: http://www.clinicaltrials.gov NCT00440193, NCT00439777 and NCT00439725
- Available from: http://www.clinicaltrials.gov NCT00643201
- Available from: http://www.clinicaltrials.gov NCT00633893
- Eriksson BI, Dahl OE, Rosencher N, Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-85
- Eriksson BI, Dahl OE, Rosencher N, Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double- blind, non-inferiority trial. Lancet 2007;370:949-56
- Ginsberg JS, Davidson BL, Comp PC, Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24:1-9
- Wolowacz SE, Roskell NS, Plumb JM, Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009;101:77-85
- Available from: http://www.clinicaltrials.gov NCT00291330
- Available from: http://www.clinicaltrials.gov NCT00680186
- Available from: http://www.clinicaltrials.gov NCT00329238
- Available from: http://www.clinicaltrials.gov; NCT00558259
- Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost 2006;96:274-84
- Sox HC, Greenfield S. Comparative effectiveness research: a report from the Institute of Medicine. Ann Intern Med 2009;151:203-5